Recent studies have explored the mechanism of resistance of BRAFV600E-mutated colorectal cancers to BRAF-inhibitors, showing that the mechanism of resistance implies alterations in elements of the RAS-RAF-MEK-ERK pathway. The gene discussed is EPHB2; the disease is colorectal cancer.